Articles tagged "Prophylaxis"

2022 American Transplant Congress
Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study
T. N. Bullard¹, C. A. Moore², J. Dasigi², L. M. Sacha², C. A. Iasella³, K. A. Shimko², E. K. McCreary⁴, F. P. Silveira⁴
¹Massachusetts General Hospital, Boston, MA, ²UPMC, Pittsburgh, PA, ³Univ of Pittsburgh, Pittsburgh, PA, ⁴Univ of Pittsburgh and UPMC, Pittsburgh, PA
*Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…
2022 American Transplant Congress
Effect of Micafungin Bridging on Prevention of Invasive Candidiasis Post Lung Transplantation
C. Baladad¹, M. Converse¹, K. DeSear¹, S. Karimi¹, E. Rubido¹, G. El Helou², T. Pasley¹
¹Pharmacy, University of Florida Health, Shands, Gainesville, FL, ²Infectious Diseases, University of Florida Health, Shands, Gainesville, FL
*Purpose: This study aims to determine the effect of micafungin, added as a bridging agent to azole antifungal prophylaxis, in lung transplantation patients with positive…
2022 American Transplant Congress
Recurrent Cytomegalovirus and the Role of Secondary Prophylaxis in Heart and Lung Transplant Recipients
S. N. Finder¹, K. Harrison¹, M. Morrison¹, S. Rega², I. Feurer², C. Gorsline³, G. Satyanarayana³, S. Hamel¹
¹Department of Pharmaceutical Sciences, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt Transplant Center, Nashville, TN, ³Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN
*Purpose: This study aimed to describe the incidence of cytomegalovirus (CMV) recurrence in heart and lung transplant recipients and the effect of secondary prophylaxis (SP)…
2022 American Transplant Congress
An Interventional Study Using Cell-Mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study
J. T. Solera¹, C. Cervera², S. Hosseini¹, J. Gill³, S. Shalhoub⁴, J. Zaltzman⁵, N. Pinzon¹, A. Humar¹, D. Kumar¹
¹UHN, Toronto, ON, Canada, ²UAlberta, Edmonton, AB, Canada, ³UBC, Vancouver, BC, Canada, ⁴LHSC, London, ON, Canada, ⁵StMH, Toronto, ON, Canada
*Purpose: There are limited interventional studies using CMV cell-mediated immunity to guide the duration of antiviral prophylaxis. We aimed to use CMV CMI to guide…
2022 American Transplant Congress
Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis
M. Z. Abidi¹, K. Garth¹, J. Gutman², A. Weinberg¹
¹Medicine, Infectious Disease, University of Colorado, Aurora, CO, ²Medicine, Hematology and Oncology, University of Colorado, Aurora, CO
*Purpose: In the absence of antiviral prophylaxis following Hematopoietic Cell Transplant (HCT), the incidence of clinically significant cytomegalovirus reactivation (cCMV) is 30% in CMV seropositive…
2022 American Transplant Congress
Evaluation of Prophylactic Valganciclovir Dosing in Kidney Transplant Recipients at an Urban Transplant Institution
E. Foster¹, D. Pierce¹, T. Cairns¹, S. Borgetti², I. Tzvetanov³, E. Benedetti³, C. Muran¹
¹Pharmacy, University of Illinois at Chicago, Chicago, IL, ²Medicine, University of Illinois at Chicago, Chicago, IL, ³Surgery, University of Illinois at Chicago, Chicago, IL
*Purpose: Dosing and duration of cytomegalovirus (CMV) prophylaxis with valganciclovir (VGC) in kidney transplant (KT) recipients is variable by transplant center. Prior studies have shown…
2022 American Transplant Congress
Incidence of Urinary Tract Infection or Asymptomatic Bacteriuria in Kidney Transplant Recipients with Sulfamethoxazole-Trimethoprim vs. Pentamidine for Pneumocystis Jiroveci Pneumonia Prophylaxis
L. Selznick, H. Sweiss, C. Long, S. Bhayana, R. Hall
University Health, San Antonio, TX
*Purpose: To compare the incidence of urinary tract infection (UTI) or asymptomatic bacteriuria (ASB) post-kidney transplant (KT) with multiple Pneumocystis jiroveci pneumonia (PJP) prophylaxis regimens*Methods:…
2021 American Transplant Congress
An Evaluation of Pjp Prophylaxis and Anemia Among Renal Transplant Recipients
J. Hedvat, N. Poladi, D. Salerno, G. Dube, N. Lange
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Dapone and atovaquone are therapeutic options for PJP prophylaxis in renal transplant recipients. The objective of this study was to evaluate the incidence of…
2021 American Transplant Congress
Breakthrough Cytomegalovirus DNAemia in High vs Intermediate Risk Heart Transplant Recipients
G. Huang¹, O. E. Beaird¹, M. Davis², M. Carlson¹, S. Chang¹, P. Gaynor¹, A. Fan², M. Deng³, A. Multani¹, A. Nsair³, J. Schaenman¹
¹Infectious Diseases, UCLA, Los Angeles, CA, ²Pharmacy, UCLA, Los Angeles, CA, ³Cardiology, UCLA, Los Angeles, CA
*Purpose: Cytomegalovirus (CMV) is one of the most common infections after transplantation and continues to cause significant morbidity and mortality despite prophylaxis and screening strategies.…
2021 American Transplant Congress
Probiotic Protocol to Reduce Perioperative Infection After Liver Transplantation
M. Jorgenson¹, Q. Yang², D. Yang², G. Leverson², C. Saddler², J. Smith², N. Safdar², L. Fernandez², D. Al-Adra²
¹UW Health, Madison, WI, ²UW School of Medicine and Public Health, Madison, WI
*Purpose: Evaluate efficacy and safety of a probiotic preparation to reduce perioperative infection in patients undergoing liver transplant surgery*Methods: Adult patients receiving liver transplantation from…